-
Summit Therapeutics (NASDAQ:SMMT) Earns "Buy" Rating from HC Wainwright
来源: Buzz FX / 22 1月 2025 02:50:17 America/New_York
Summit Therapeutics (NASDAQ:SMMT) Earns "Buy" Rating from HC Wainwright Written by MarketBeat January 22, 2025 Share Link copied to clipboard. HC Wainwright reissued their buy rating on shares of Summit Therapeutics ( NASDAQ:SMMT - Free Rep
Read more...